[{"id":"c579a27c-265f-45f8-af31-1763b1f84a7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05164458","created_at":"2021-12-20T15:53:45.428Z","updated_at":"2024-07-02T16:35:24.966Z","phase":"Phase 1","brief_title":"Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies","source_id_and_acronym":"NCT05164458","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • IBI-389"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-28"}]